6
Participants
Start Date
June 28, 2023
Primary Completion Date
September 16, 2024
Study Completion Date
September 16, 2024
IMSA101
Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.
Immune checkpoint inhibitor
1st infusion on Cycle 1 Day 2, and then thereafter as per product label
PULSAR
1st day of Cycles 1, 2 and 3.
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Louis Stokes Cleveland VA Medical Center, Cleveland
MetroHealth Medical Center, Cleveland
University of Wisconsin Hospital and Clinics, Madison
The University of Kansas Medical Center, Kansas City
Baylor College of Medicine Medical Center, Houston
Huntsman Cancer Institute, University of Utah, Salt Lake City
City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Rutgers Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
ImmuneSensor Therapeutics Inc.
INDUSTRY